tbuckley/cabot-search huggingface dataset:
Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer.
Authors: C. R. Heery, P. A. Pinto, J. Schlom, K. Y. Tsang, R. A. Madan, D. Poole, M. Vergati, B. Walter Rodriguez, M. Merino, J. L. Gulley
Journal: Journal of Clinical Oncology (2011)

2530 Background: PSA-TRICOM is a cancer vaccine composed of recombinant poxviruses with transgenes for PSA and 3 T cell costimulatory molecules (TRICOM). In a multicenter randomized vector controlled phase II study median overall survival improved by 8.5 months in men with metastatic CRPC. Preclinical studies show intratumoral administration of TRICOM vaccines may improve anti-tumor effect. This study intended to show safety of intraprostatic (i.p.) vaccine administration. 2° goals were immunologic and tumor response. Methods: 21 pts with locally recurrent prostate cancer after radiation were enrolled into 5 cohorts and received initial vaccination with s.c. recombinant vaccinia (rV)-PSA-TRICOM and booster i.p. recombinant fowlpox (rF)-PSA-TRICOM. Cohorts 3-5 also received i.p. rF-GM-CSF. Cohort 5 received concurrent s.c. and i.p. boosters. Priming was given on day 1. Boosters were given on days 29, 57, and 85. Pts had pre- and post-treatment prostate biopsies. Tumor infiltrate was evaluated when adequate tissue was available. PBMCs were analyzed by ELISPOT for response to PSA and 3-color flow cytometry to characterize regulatory T cells (Treg) or effector T cells. Treg suppression function was assayed by suppression of the CD4+ effector T cell proliferation. Results: Only 1 grade 3 toxicity occurred, a transient fever. Most common grade 2 adverse events for all doses were fever (14.5%) and injection-site reactions (21%). 18 of 21 pts had stable or improved PSA on study. 16 of 21 pts had stable or improved PSA doubling time. Post-vaccination, 4 of 8 evaluable pts had immune response by ELISPOT and 11 of 15 pts had decreased (n=8) or stable (n=3) Treg function. A paired t-test of 13 biopsies pre- and post-vaccination showed increases in tumor immunologic infiltrates. CD3+ cells increased from 12.3 → 21.3/high power field (hpf) (p=0.0079). CD4+ cells increased from 1.3 →13.1/hpf (p=0.0002). CD8+ cells rose from 6.4 →14/hpf (p=0.0002). Conclusions: I.p. administration of PSA-TRICOM is safe, feasible and can generate a substantial immune response. Improved PSA kinetics and intense post-vaccination immune infiltrates were seen in the majority of pts. Trials of i.p. PSA-TRICOM with clinical endpoints are warranted.
OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)
Authors: Arun Rajan, Christopher Heery, Andrew Mammen, Stefania Pittaluga, Lauren Lepone, Renee Donahue, Italia Grenga, Jeffrey Schlom, James Gulley, Raffit Hassan
Journal: Journal of Thoracic Oncology (2017)
P3.02b-029 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients
Authors: Peter Berzinec, Lukas Plank, Lucia Copakova, Peter Kasan, Aster Alemayehu, Gabriela Chowaniecova, Anna Farkasova, Robert Godal, Peter Hlavcak, Michal Konecny, Martin Kucma, Livia Rotikova, Monika Slavikova, Peter Vasovcak
Journal: Journal of Thoracic Oncology (2017)
Platelet aggregation and thromboxane B2 release in patients with acute myocardial infarction. Their relation to coronary patency.
Authors: Yoshiki Takatsu, Yoshiki Yui, Ryuichi Hattori, Keiji Sakaguchi, Takashi Susawa, Natsuko Yui, Mamoru Takahashi, Takeshi Aoyama, Shunichi Tamaki, Chuichi Kawai
Journal: Circulation (1988)

Platelet function in the aortic blood in 39 patients who underwent intracoronary thrombolysis with urokinase was evaluated in the acute stage of myocardial infarction and after 4 weeks. The patients were classified into 2 groups according to the patency of the infarct vessel shown by coronary arteriography before urokinase administration. In the acute stage, 26 patinets with completely occluded infarct vessel (group 1) showed a decreased level of platelet aggregation induced by adenosine diphosphate or arachidonic acid as compared with 13 patients with patent infarct vessel (group 2). The platelet aggregation in group 1 increased 4 weeks later and both groups showed similarly enhanced platelet aggregation levels as compared with normal controls. Like platelet aggregation, serum thromboxane B2 production in group 1 was lower than that in group 2 in the acute stage. Plasma thromboxane B2 levels in the aorta in both groups were significantly elevated in the acute stage, and were normalized after 4 weeks. This elevation of thromboxane B2 seems to be due to its washout from the infarct vessel, because plasma thromboxane B2 levels were significantly higher in the great cardiac vein than those in the aorta after successful reperfusion in group 1 or group 2. In conclusion, despite a significant elevation in plasma thromboxane B2 levels, platelet aggregation and serum thromboxane B2 production relatively decrease in patients with totally occluded infarct vessel. The patency of the infarct vessels should be taken into account when evaluating platelet function in acute myocardial infarcion.
P3.02c-031 Immune Checkpoint Inhibitors (IC) and Paradoxical Progressive Disease (PPD) in a Subset of Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: Jihene Lahmar, Laura Mezquita, Serge Koscielny, Francesco Facchinetti, Maria Bluthgen, Julien Adam, Jordi Remon, Anas Gazzah, David Planchard, Jean-Charles Soria, Caroline Caramella, Benjamin Besse
Journal: Journal of Thoracic Oncology (2017)
Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome
Authors: Santhosh Dhanraj, Anna Matveev, Hongbing Li, Supanun Lauhasurayotin, Lawrence Jardine, Michaela Cada, Bozana Zlateska, Chetankumar S. Tailor, Joseph Zhou, Roberto Mendoza-Londono, Ajoy Vincent, Peter R. Durie, Stephen W. Scherer, Johanna M. Rommens, Elise Heon, Yigal Dror
Journal: Blood (2017)
Fludarabine Versus Fludarabine Plus Epirubicin in the Treatment of Chronic Lymphocytic Leukemia - Final Results of a German Randomized Phase-III Study.
Authors: Mathias J. Rummel, Stephan Stilgenbauer, Heinold Gamm, Andreas Rost, Doehner Hartmut, Dieter Hoelzer, Lothar Bergmann
Journal: Blood (2005)
Increased Radioresistance of 32Dcl3 Murine Hematopoietic Progenitor Cells by Mitochondrial Targeting of a Catalase Transgene Product.
Authors: Michael W. Epperly, J. Andres Melendez, Xichen Zhang, Darcy Franicola, Tracy Smith, Benjamin Greenberger, Paavani Komanduri, Joel S. Greenberger
Journal: Blood (2007)
P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC)
Authors: Robert Doebele, Leora Horn, Alexander Spira, Zofia Piotrowska, Daniel Costa, Joel Neal, William Reichmann, David Kerstein, Shuanglian Li, Pasi Jänne
Journal: Journal of Thoracic Oncology (2017)
Discrepancy in Detecting Bcr-Abl Kinase Domain Mutations between Cells from Bone Marrow and Cells from Peripheral Blood, and Greater Concordance between Bone Marrow Cells and Plasma Free RNA.
Authors: W. Ma, H. Kantarjian, I. Jilani, M. Gorre, Ottmann, K. Bhalla, F. Giles, M. Albitar
Journal: Blood (2005)
High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).
Authors: Frits van Rhee, Yazan Alsayed, Michele H. Cottler-Fox, Jeff Haessler, Sarah Waheed, Bijay Nair, John Crowley, Elias Anaissie, Bart Barlogie
Journal: Blood (2009)
P146 Mortality and day of admission for acute exacerbation of copd
Authors: A Duffy, J Steer, SC Bourke, C Echevarria
Journal: Thorax (2016)

<h3>Background</h3> Excess mortality in patients admitted to hospital at weekends has been reported in many healthcare systems, influencing healthcare policy. The limitations of existing data are well described; there is a need for condition-specific research in well-described populations with adjustment for baseline mortality risk.<sup>1</sup> Acute exacerbations of COPD (AECOPD) are one of the commonest reasons for hospital admission, with high rates of inpatient mortality. We aimed to establish if inpatient mortality is associated with day of admission or death amongst patients admitted with an AECOPD. <h3>Methods</h3> Consecutive admissions from six UK hospitals were identified from the DECAF derivation and validation studies.<sup>2</sup> All patients (n = 2,645) had definite COPD (including spirometric confirmation) and the primary reason for admission was AECOPD. DECAF indices (dypsnoea, eosinopenia, consolidation, acidaemia and atrial fibrillation) and age were collected. We captured the number of inpatient deaths per day of admission (compared to the total number of admissions on each day) and per day of death (compared to the total number of bed days for each day). Proportions were compared using Fisher’s exact test. The association between period of admission (weekday/weekend) and mortality was assessed in a binary logistic regression model, including the DECAF indices and age. <h3>Results</h3> Inpatient mortality was 9.3% (63/676) for those admitted on weekends, compared to 8.4% (165/1969) on weekdays (p = 0.47). For day of death, no clear difference in mortality was seen between weekdays and weekends although fewer deaths were seen on Fridays. Exacerbation severity was similar between weekday and weekend admissions (median DECAF score 2 vs. 2, p = 0.83). Following adjustment for baseline mortality risk, there was no association between weekend admission and inpatient death; OR 1.11 (0.79 to 1.56), p = 0.55. <h3>Discussion</h3> In a well-described population with an AECOPD, there is no relationship between inpatient mortality and day of admission or day of death, even after adjusting for baseline mortality risk. <h3>References</h3> Becker DJ. <i>Expert Rev Pharmacoecon Outcomes Res</i> 2008. Echevarria C, <i>et al</i>. <i>Thorax</i> 2016.
Antineutrophil Antibodies Lead to Mistaken Identity in Severe Congenital Neutropenia.
Authors: Laurence A. Boxer, Audrey Anna Bolyard, Beate Schwinzer, Darryl Glaser, Kenneth Dougan, Mary Ann Bonilla, Blanche P. Alter, Bonnie Cham, Sally E. Kinsey, Connie Zeidler, Karl Welte, David C. Dale
Journal: Blood (2005)
P2.03b-068 The Druggable Mutation Landscape of Lung Adenocarcinoma
Authors: Anika Gupta, Caitlin Connelly, Garrett Frampton, Juliann Chmielecki, Siraj Ali, James Suh, Alexa Schrock, Jeffrey Ross, Philip Stephens, Vincent Miller
Journal: Journal of Thoracic Oncology (2017)
Requirements for Co-Stimulation in T-Cell Dependent and T-Cell Independent Re-Stimulation of FVIII-Specific Memory B Cells
Authors: Aniko Ginta Pordes, Christina Hausl, Peter Allacher, Rafi Uddin Ahmad, Eva M Muchitsch, Hartmut J Ehrlich, Hans Peter Schwarz, Birgit M Reipert
Journal: Blood (2008)
P1.03-020 FDG-PET SUVmax Does Not Correlate with Glucose Metabolism in Non-Small Cell Lung Cancer
Authors: Kemp Kernstine, Brandon Faubert, Christopher Hensley, Ling Cai, Jose Torrealba, Dwight Oliver, Robert Lenkinski, Craig Malloy, Ralph Deberardinis
Journal: Journal of Thoracic Oncology (2017)
Vital Signs: Decrease in Incidence of Diabetes-Related End-Stage Renal Disease among American Indians/Alaska Natives — United States, 1996–2013
Authors: Ann Bullock, Nilka Ríos Burrows, Andrew S. Narva, Karen Sheff, Israel Hora, Akaki Lekiachvili, Hannah Cain, David Espey
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

American Indians and Alaska Natives (AI/AN) have the highest diabetes prevalence among any racial/ethnic group in the United States. Among AI/AN, diabetes accounts for 69% of new cases of end-stage renal disease (ESRD), defined as kidney failure treated with dialysis or transplantation. During 1982-1996, diabetes-related ESRD (ESRD-D) in AI/AN increased substantially and disproportionately compared with other racial/ethnic groups.
FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma
Authors: Denise Casey, Suzanne Demko, Stacy Shord, Hong Zhao, Huanyu Chen, Kun He, Alexander Putman, Whitney Helms, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research (2017)

Abstract On July 24, 2015, the FDA approved sonidegib (ODOMZO; Novartis) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy. The approval was based on data from one randomized, double-blind, noncomparative trial of two doses of sonidegib administered to 230 hedgehog inhibitor–naïve patients with metastatic basal cell carcinoma (mBCC, n = 36) or laBCC (n = 194). Patients were randomized 2:1 to receive sonidegib 800 mg (n = 151) or 200 mg (n = 79) daily. The objective response rate (ORR) for patients with laBCC was 58% [95% confidence interval (CI), 45–70] in the 200 mg group and 44% (95% CI, 35–53) in the 800 mg group. The median duration of response for patients with laBCC was nonestimable (NE) in the 200 mg arm and 15.7 months (95% CI, NE) in the 800 mg arm. The ORR for patients with mBCC was 8% (95% CI, 0.2–36) and 17% (95% CI, 5–39) in patients treated with 200 and 800 mg, respectively. The most common adverse events occurring in ≥10% of patients were muscle spasms, alopecia, dysgeusia, nausea, fatigue, increased serum creatine kinase, decreased weight, and diarrhea. Clin Cancer Res; 23(10); 2377–81. ©2017 AACR.
Treatment of traveler's diarrhea with sulfamethoxazole and trimethoprim and loperamide
Authors: C. D. Ericsson
Journal: JAMA (1990)

In a randomized, double-blind, placebo-controlled trial, 227 US adults with acute diarrhea in Mexico received a single dose of sulfamethoxazole and trimethoprim (1600/320 mg) or 3 days of therapy with loperamide hydrochloride (4-mg loading dose, then 2 mg orally after each loose stool), sulfamethoxazole-trimethoprim (800/160 mg orally twice daily), or the combination of both. Subjects treated with the combination had the shortest average duration of diarrhea compared with the placebo group (1 hour vs 59 hours), took the least amount of loperamide after the loading dose (3.8 mg), and had the shortest duration of diarrhea associated with fecal leukocytes or blood-tinged stools (4.5 hours). A single dose of sulfamethoxazole-trimethoprim was also efficacious (28 vs 59 hours), but loperamide alone was significantly effective only when treatment failures were treated with antibiotics (33 vs 58 hours). The combination of sulfamethoxazole-trimethoprim plus loperamide can be highly recommended for the treatment of most patients with travelers diarrhea. (<i>JAMA</i>. 1990;263:257-261)
bcl-2 Translocation [t(14;18) (q32;q21)] Does Not Correlate with Poor Clinical Outcome in Multiple Myeloma Patients Treated with Bortezomib.
Authors: Sikander Ailawadhi, Terry L. Mashtare, Marie V. Coignet, Dawn M. DePaolo, Kena C. Miller, Swaminathan Padmanabhan, Gregory Wilding, Petr Starostik, Asher A. Chanan-Khan
Journal: Blood (2007)
P51 Clinical effectiveness of procalcitonin based protocols to guide the administration of antibiotics in patients presenting with COPD exacerbations: systematic review and meta-analysis
Authors: AG Mathioudakis, V Chatzimavridou-Grigoriadou, A Corlateanu, J Vestbo
Journal: Thorax (2016)

<h3>Background</h3> Different types of acute exacerbations of COPD (AECOPD) have been described, such as those driven by bacteria, viruses or by enhanced eosinophilic inflammation. Bacterial infections, where antibiotics are indicated, appear to account for approximately half of COPD exacerbations. However, challenges in differentiation of the aetiology of AECOPD have led to significant overuse of antibiotics. Serum procalcitonin, released in response to bacterial but not viral infections or non-specific inflammation, could possibly identify AECOPD requiring antibiotics. In this meta-analysis we assessed safety and clinical effectiveness of procalcitonin-based protocols to initiate or discontinue antibiotics in patients presenting with AECOPD. <h3>Methods</h3> Based on a prospectively registered protocol, we systematically reviewed the literature and selected randomised or quasi-randomised controlled trials comparing procalcitonin based protocols to initiate or discontinue antibiotics in patients presenting with AECOPD versus standard care. We followed Cochrane’s and GRADEs guidance to assess risk of bias, quality of evidence and to perform meta-analyses. <h3>Results</h3> Eight completed trials evaluating 1,062 patients with AECOPD met the inclusion criteria. Procalcitonin-based protocols used in all included trials were similar. Antibiotics were recommended for procalcitonin levels &gt;0.25 μg/L and discouraged for lower levels. All studies were open-labelled or single blinded and the final decision to administer or withhold antibiotic was left to the responsible clinician, who could deviate from the protocol. Adherence to procalcitonin-based protocols ranged between 61.3% and 98.1%. Procalcitonin-based protocols decreased antibiotic prescription (RR 0.56 [0.43, 0.73]) and the total antibiotic exposure (MD −3.83 [−4.32, −3.35]), without affecting clinical outcomes such as rate of treatment failure (RR 0.81 [0.62, 1.06]), length of hospitalisation (MD −0.76 [−1.95, 0.43]), exacerbation recurrence rate (RR 0.96 [0.69, 1.35]) or mortality (RR 0.99 [0.57, 1.70]). However, the quality of the available evidence is low to moderate because of methodological limitations and small overall study population. <h3>Conclusion</h3> Procalcitonin-based protocols to guide the administration of antibiotics in patients presenting with AECOPD appear safe and clinically effective. The quality of the available evidence is low-to-moderate because of methodological limitations and small overall population. Thus, additional appropriately designed and powered confirmatory randomised controlled trials are required.
Detection of metastatic lymph nodes of para-aortic or pelvic area by measuring the size of lymph nodes (LNs) before lymphadenectomy in gynecologic malignancy.
Authors: Y. Itani, T. Kita, C. Uekuri, J. Akasaka, H. Hirano, M. Kawa, S. Toyoda
Journal: Journal of Clinical Oncology (2011)

e15560 Background: To compare the size of lymph nodes (LNs) of para-aortic or pelvic area between metastatic and non-metastatic LNs retrospectively in pathologically confirmed lymph node positive gynecologic malignancy. Methods: The lengths of major axis and thickness of all dissected LNs were measured by gage on specimen slides in pathologically confirmed LN positive (LN+) 18 gynecologic malignant patients. Student t test was used for statistically analysis. Results:The size of 821 LNs, 196 para-arotic LNs (PAN) and 625 pelvic LNs (PN) were measured from 8 of cervical cancer, 5 of endometrial cancer, and 5 of ovarian cancer. The median number of dissected LNs was 44 (ranged 16 to 97) per case. Twenty-seven PAN (PAN+) and 62 PN (PN+) were ascertained with metastasis of primary cancer. Median major axis and thickness of LN+ were 9.7mm (95% confidential interval (CI); 9.0, 10.5) and 5.4mm (95%CI; 5.0, 5.8) and median those of non-metastasized LN (LN-) were 4.2mm (95%CI; 3.9, 4.4) and 2.2mm (95%CI; 2.1, 2.4). There were statistically differences between the two groups (p<0.0001). In subgroup analysis, median major axis (8.5mm [95%CI; 7.2, 9.7]) and thickness (4.8mm [95%CI; 4.2, 5.5]) of PAN+ were statistically larger (p<0.0001) than those (3.9mm [95%CI; 3.4, 4 .4] and 2.3 mm [95%CI; 2.0, 2.6]) of PAN-. And also, median major axis (10.3mm [95%CI; 9.3, 11.2]) and thickness (5.7mm [95%CI; 5.2, 6.2]) of PN+ were statistically larger (p<0.0001) than those (4.2mm [95%CI; 3.9 4.5] and 2.2 mm [95%CI; 2.1, 2.4]) of PN-. Conclusions: The size of metastatic LNs increases in both major axis and thickness. If we could detect 7.2 mm in major axis or 4.2 mm in thickness of PAN or 9.3 mm in major axis or 5.2 mm in thickness of PN, it would be possible to skip lymphadenectomy of para-aortic or pelvic area with 95%CI by pre- or intra-surgical evaluation.
The Novel Cancer Drug Seliciclib Engages the Mitochondrial Apoptosis Pathway Via the Mcl-1/Noxa Axis in CLL.
Authors: Delfine Hallaert, Rene Spijker, Ingrid A.M. Derks, Margot Jak, Bart de Goeij, Jan Paul de Boer, Daphne de Jong, Simon R. Green, Rene van Lier, Eric Eldering, Marinus H.J. Van Oers
Journal: Blood (2005)
P3.02b-081 Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Authors: Ramon Andrade De Mello, Pedro Aguiar, Paloma Cabral, Fábio Chaves, Davi Liu, Joao Paulo Soares, Giannis Mountzios, Hakaru Tadokoro, Gilberto De Lima Lopes
Journal: Journal of Thoracic Oncology (2017)
Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.
Authors: Ajay K. Kakkar, Benjamin Brenner, Ola E. Dahl, Bengt I. Eriksson, Patrick Mouret, Jim Muntz, Tiemo J. Bandel, Frank Misselwitz, Sylvia Haas
Journal: Blood (2007)
Conservative management of lateral hip pain: the future holds promise
Authors: Alison Grimaldi
Journal: British Journal of Sports Medicine (2017)

It goes by many names but lateral hip pain, essentially gluteal tendinopathy has a profound impact on quality of life and activity level. Currently, there is little high-level evidence as to how to manage it.

In the systematic review regarding greater trochanteric pain syndrome (GTPS) Barratt et al 1 found only eight non-surgical treatment studies eligible for review. Of these, all but one had a moderate-to-high risk of bias. The strongest evidence, both in terms of study design and outcomes, is for corticosteroid injection (CSI). With pain reduction occurring in the majority of patients within 4 weeks, it is not surprising that CSI is often the first line of treatment in general medical practice. Similar to responses to CSI seen in other tendinopathies however, recurrence is common and success rates fall over time, making this approach no more effective in the longer term than adopting a wait-and-see approach. While acute complications following CSI are rare, concerns remain regarding potential negative effects on the tendon associated with down regulation …
Clinical Presentation, Prognostic Factors and Treatment Outcome of Multiple Myeloma (MM) in African American (AA) Patients.
Authors: Ashraf Z. Badros, Olga Goloubeva, Saranya Chumsri, Kathleen Ruehle, Yi Ning, Joann Meekins, Liliana Guedez, Aaron P. Rapoport, Barry Meisenberg, Gorgun Akpek, Saul Yanovich, Edward Sausville
Journal: Blood (2006)
Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL
Authors: Tait Shanafelt, Han Tun, Curtis Hanson, Clive S. Zent, Jose Leis, Timothy Call, Betsy LaPlant, Deborah Bowen, Kristina Laumann, Diane F. Jelinek, Neil E. Kay
Journal: Blood (2010)
A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL.
Authors: Jennifer R Brown, Jeremy S. Abramson, Ephraim P. Hochberg, Evgeny Mikler, Virginia Dalton, Hazel Reynolds, Jennifer Romano, Lillian Werner, Christina Thompson, Sean McDonough, Jerome Ritz, Donna Neuberg, Arnold S. Freedman
Journal: Blood (2009)
P3.01-021 Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumor Nodules
Authors: Andrew Nicholson, Patrizia Viola, Kathleen Torkko, Edwina Duhig, Kim Geisinger, Alain Borczuk, Kenzo Hiroshima, Ming Tsao, Arne Warth, Sylvie Lantuejoul, Prudence Russell, Erik Thunnissen, Alberto Marchevsky, Mari Mino-Kenudson, Mary Beth Beasley, Johan Botling, Sanja Dacic, Yasushi Yatabe, Masayuki Noguchi, William Travis, Keith Kerr, Fred R. Hirsch, Lucian Chirieac, Ignacio Wistuba, Andre Moreira, Jin-Haeng Chung, Teh Ying Chou, Lukas Bubendorf, Gang Chen, Giuseppe Pelosi, Claudia Poleri, Wilbur Franklin
Journal: Journal of Thoracic Oncology (2017)
MA04.03 Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC
Authors: Shengxiang Ren, Caicun Zhou, Guanghui Gao, Chunxia Su, Xiaoxia Chen, Feng Ying Wu, Xuefei Li, Chao Zhao, Weijing Cai
Journal: Journal of Thoracic Oncology (2017)